ADIPOQ and Insulin resistance: This resistance, characterized by increased circulating FGF21 and decreased receptor expression, has been associated with a compensatory increase in adiponectin levels in obese individuals, those with insulin resistance, and heart failure patients (Holland et al., 2013; Lin et al., 2013).